1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Prostate cancer (PC) is a leading cause of cancer death in men, with the androgen receptor (AR) as a primary therapeutic target.
• Disease progression to androgen-independent forms necessitates the development of novel AR antagonists.
• Existing nonsteroidal antiandrogens share a common scaffold structure.

Purpose of the Study:

• To synthesize and evaluate a novel library of 1,4-substituted triazoles as potential AR antagonists.
• To investigate the impact of incorporating a triazole core into antiandrogen scaffolds.
• To identify potent small molecules for improved AR-antagonist activity in prostate cancer.

Main Methods:

• Facile, one-pot click chemistry reaction for triazole synthesis.
• Biological evaluation of synthesized compounds for AR antagonistic activity.
• In vitro testing against prostate cancer cell lines and in vivo xenograft models.

Main Results:

• A library of novel 1,4-substituted triazoles with AR antagonistic activity was successfully prepared.
• The introduction of the triazole core enhanced the overall AR-antagonist activity of the small molecules.
• Compound 14d demonstrated potent in vitro antitumor activity and 60% tumor growth inhibition in an in vivo xenograft model.

Conclusions:

• Novel triazole-based compounds exhibit promising AR antagonist properties.
• These findings represent a significant step towards developing improved therapeutic agents for prostate cancer.
• The developed compounds offer a new strategy for targeting AR in both androgen-dependent and -independent prostate cancer.